Should You Buy Kenvue Stock At $22? [Forbes]
Johnson & Johnson (JNJ)
Last johnson & johnson earnings: 4/14 06:31 am
Check Earnings Report
US:NYSE Investor Relations:
jnj.com
Company Research
Source: Forbes
Our thorough analysis encompassing growth, profitability, financial stability, and valuation metrics uncovers fundamental weaknesses that render the stock unattractive for new investors at this time. Kenvue became an independent entity in May 2023 after its spinoff from Johnson & Johnson's consumer health division. As a global consumer health company, Kenvue has shifted from being part of a healthcare conglomerate to functioning as a standalone public company within a competitive consumer products market. That being said, if you are looking for upside with less volatility compared to individual stocks, the Trefis High Quality portfolio serves as an alternative — having outperformed the S&P 500 and delivered returns that exceed 91% since its establishment. Also, see – UNH Stock To $160? Valuation Analysis: Premium Pricing Kenvue is trading at a considerable premium to the overall market across key valuation metrics: Price-to-Earnings (P/E): 40.7x compared to the S&P 500's 22.
Show less
Read more
Impact Snapshot
Event Time:
JNJ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
JNJ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
JNJ alerts
High impacting Johnson & Johnson news events
Weekly update
A roundup of the hottest topics
JNJ
News
- Johnson & Johnson Terminates Trial of Atopic Dermatitis Drug Candidate [Yahoo! Finance]Yahoo! Finance
- Johnson & Johnson halts mid-stage trial of experimental eczema drug [CNBC]CNBC
- Business Insider staff share their favorite books of 2025 [Business Insider]Business Insider
- Is Johnson & Johnson's (JNJ) Recent Rally Still Leaving the Stock Undervalued? [Yahoo! Finance]Yahoo! Finance
- Here's Why Johnson & Johnson (JNJ) Surged in Q3 [Yahoo! Finance]Yahoo! Finance
JNJ
Earnings
- 10/14/25 - Beat
JNJ
Sec Filings
- 12/11/25 - Form 4
- 12/11/25 - Form 4
- 12/11/25 - Form 4
- JNJ's page on the SEC website